1991
Lipogen established as partnership between company founders and two pioneering scientists – Professor Meir Shinitzky and Dr. Avner Sheinfeld –from the renowned Weizmann Institute.
Lipogen introduces the world’s first vegan-source formula for specific molecules vital to brain health.
1992
Lipogen builds upon the Weizmann Institute’s research success, progressing to formal formula development and clinical research.
Lipogen demonstrates the positive effects of the Lipogen PSPA formula on memory performance in healthy individuals. The results show that people who use the formula significantly improve their memory and mood.
1995
The company conducts a clinical study that shows significant positive impact of the Lipogen PS Plus formula on Alzheimer’s disease patients’ daily functioning, emotional state and general condition, with no side effects.
2003
The US Food and Drug Administration (FDA) grants the primary Lipogen ingredient phosphatidylserine (PS) a Qualified Health Claim approval, allowing Lipogen to specify on its label that consumption of PS “may reduce the risk of dementia or cognitive dysfunction in the elderly.”
In 2019, PS is still the only nutritional supplement that has this claim approval (in the proper dose), while other supplement-claim requests have been rejected by the FDA.
2004
Lipogen conducts an independent clinical study examining the effects of the Lipogen PSPA formula on the stress hormone cortisol. When the level of cortisol in the body remains abnormally high, people are at higher risk of health problems.
Results from the scientific study show that subjects who take Lipogen PSPA function better and have lower levels of cortisol during and after stressful events.
2006
Lipogen formulas are designated Generally Recognized As Safe (GRAS) by the FDA. To obtain this approval, companies must prepare a comprehensive product safety portfolio, including a detailed analysis and characterization of the formula’s ingredients and the production process. The FDA reviews scientific information, clinical trial results and toxicology reports demonstrating product safety.
2010
Lipogen signs a collaboration agreement with the large Swiss pharmaceutical company, Lonza.
2014
Lipogen publishes results of the clinical trial that assesses the effects of the formula on people’s cortisol stress hormone levels. There is large and growing evidence worldwide about the correlation of high cortisol levels and Alzheimer’s disease.
Lipogen proves again that subjects taking the formula suffer from less emotional stress, function better in stressful situations and have lower cortisol hormone levels than subjects who do not take the formula.
2016
Following successful formula safety and efficacy studies, Lipogen receives the European Union’s most prestigious safety certificate NOVEL FOOD.
This extensive approval process includes submitting a detailed application, including in-depth ingredient data and characteristics, information of the production process, an analysis of various risk factors, stability data, use and level of exposure, history of exposure to the complex and a comprehensive toxicology report.
2018
The company publishes a clinical study that examines the positive effects of the formula on women with premenstrual syndrome (PMS) The results show that women who take the formula demonstrate significant improvement in emotional, physical and performance symptoms over 3 menstrual cycles, including lower depression and less interference in relationships and productivity.
